TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10680107

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.05 mg/kg (ED95)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg/kg (2 x ED95)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.025 mg/kg (0.5 x ED95)
Number of subjects: 40
Study: 8765865

Group type: EXPERIMENTAL
Intervention: 8 ml 0.5% bupivacaine + 0.1 mg fentanyl (B+F group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: 8 ml 0.5% bupivacaine + 2 ml saline (Bup group)
Number of subjects: 43
Study: 1658407

Group type: EXPERIMENTAL
Intervention: NDP (Nle4D-Phe7) alpha-MSH
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 28
Study: 7202950

Group type: COMPARATOR
Intervention: Pneumatic forceful dilatation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Surgical esophagomyotomy
Number of subjects: 38
Study: 31863758

Group type: EXPERIMENTAL
Intervention: Increased end of surgery to baseline ratio of neuroserpin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Concentrations of neuroserpin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Glial fibrillary acidic protein, phosphorylated axonal neurofilament subunit H, and visinin-like protein 1
Number of subjects: 100
Study: 30925948

Group type: EXPERIMENTAL
Intervention: Small-dose ropivacaine hydrochloride (1 mL) combined with fentanyl (10 µg)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Large-dose ropivacaine hydrochloride (1.5 mL)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Small-dose ropivacaine hydrochloride combined with fentanyl
Number of subjects: 134
Study: 28493623

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg over 8 days)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 26408488

Group type: EXPERIMENTAL
Intervention: Video version of the Web-based computer-tailored obesity prevention intervention
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Text version of the Web-based computer-tailored obesity prevention intervention
Number of subjects: 1419

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored obesity prevention intervention (both video and text)
Number of subjects: 1419

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored obesity prevention intervention
Number of subjects: 1419
Study: 22446565

Group type: EXPERIMENTAL
Intervention: Valacyclovir (1.5 g twice daily for 18 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22554310

Group type: EXPERIMENTAL
Intervention: Teachable Moments Communication Process (TMCP) intervention for smoking cessation
Number of subjects: 840

Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 840
Study: 20017356

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg daily for 30 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nimesulide 100 mg BID for 30 days
Number of subjects: 80
Study: 17415683

Group type: EXPERIMENTAL
Intervention: US preference weights
Number of subjects: 1126

Group type: COMPARATOR
Intervention: UK preference weights
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: US and UK preference weights
Number of subjects: 1126
Study: 11199242

Group type: EXPERIMENTAL
Intervention: Multimedia program in Dalby
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group in S Sandby
Number of subjects: 800
Study: 8689337

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone followed by oral cefixime
Number of subjects: 80
Study: 1620430

Group type: EXPERIMENTAL
Intervention: Continuous ev type anesthesia (AEC) using propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced anesthesia (AB)
Number of subjects: 0
Study: 6366811

Group type: EXPERIMENTAL
Intervention: Ordinary metoprolol tablets (100 mg twice daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sustained-release metoprolol tablets (200 mg once daily)
Number of subjects: 10
Study: 30415084

Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressure monitoring
Number of subjects: 80
Study: 29852038

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study: 26716932

Group type: EXPERIMENTAL
Intervention: ACT OPEN module
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ACT ENGAGED module
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both modules
Number of subjects: 15
Study: 24418366

Group type: EXPERIMENTAL
Intervention: Intervention (depression care management with treatment adherence support and interpersonal psychotherapy if desired)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 417
Study: 22019201

Group type: EXPERIMENTAL
Intervention: High protein meal (HiPro Fru meal) after hyper-energetic high fructose diet (HiFruD)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High protein meal (HiPro Fru meal) after hyper-energetic high fructose high protein diet (HiFruHiProD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low protein meal (Fru meal) after hyper-energetic high fructose diet (HiFruD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low protein meal (Fru meal) after hyper-energetic high fructose high protein diet (HiFruHiProD)
Number of subjects: 8
Study: 20471273

Group type: EXPERIMENTAL
Intervention: Physiotherapeutic group training including gait and balance exercises with function-oriented strengthening (N=35)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (N=36)
Number of subjects: 71
Study: 17117432

Group type: EXPERIMENTAL
Intervention: Feeding jejunostomy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nasoduodenal tube
Number of subjects: 150
Study: 16260510

Group type: EXPERIMENTAL
Intervention: Hormone therapy (daily oral conjugated estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 1208
Study: 12099947

Group type: EXPERIMENTAL
Intervention: Patient-held record (PHR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no PHR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Primary healthcare (PHC) professionals
Number of subjects: 100
Study: 9988782

Group type: EXPERIMENTAL
Intervention: Lower dose nutritional formula (Myer's Cocktail)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Higher dose nutritional I/V
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 64
Study: 7568735

Group type: EXPERIMENTAL
Intervention: Periotest method
Number of subjects: 0
Study: 2405610

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP)
Number of subjects: 39
Study: 31273529

Group type: EXPERIMENTAL
Intervention: Lined with resin‐modified glass ionomer (RMGIC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Unlined cavities
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both lined and unlined restorations
Number of subjects: 39
Study: 30851166

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (esomeprazole 40 mg, amoxicillin 1 g for 5 days, followed by esomeprazole 40 mg, clarithromycin 500 mg, and tinidazole 500 mg for 5 days)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: 14-day sequential therapy (esomeprazole 40 mg, amoxicillin 1 g for 7 days, followed by esomeprazole 40 mg, clarithromycin 500 mg, and tinidazole 500 mg for 7 days)
Number of subjects: 291
Study: 27677565

Group type: EXPERIMENTAL
Intervention: MIE with CEA
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: MIE with IEA
Number of subjects: 356
Study: 25329822

Group type: EXPERIMENTAL
Intervention: Fentanyl (100 μg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 100
Study: 23828423

Group type: EXPERIMENTAL
Intervention: Endouterine hemostatic square suture
Number of subjects: 13

Group type: COMPARATOR
Intervention: Bakri balloon tamponade
Number of subjects: 13
Study: 21846796

Group type: EXPERIMENTAL
Intervention: Methyl selenocysteine, single-dose, pharmacokinetics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selenomethionine, 200 μg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selenized yeast (NPC agent)
Number of subjects: 0
Study: 20484768

Group type: EXPERIMENTAL
Intervention: Actual visuo-proprioceptive practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visuo-proprioceptive imagery practice
Number of subjects: 0
Study: 17014927

Group type: EXPERIMENTAL
Intervention: Ultrasonography for detecting endotracheal tube placement
Number of subjects: 33
Study: 16368046

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene (pooled groups)
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study: 11812709

Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 30

Group type: COMPARATOR
Intervention: Passive insulation
Number of subjects: 30
Study: 9814500

Group type: EXPERIMENTAL
Intervention: CRH‐R1 mRNA in the LS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRH‐R2 mRNA in the LS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRH‐R1 and CRH‐R2 protein localization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRH‐R1 mRNA presence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRH‐R2 mRNA presence
Number of subjects: 0
Study: 7699607

Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 0
Study: 2560284

Group type: EXPERIMENTAL
Intervention: Enalapril (E), 10 mg/day for four weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 22
Study: 203308

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31688450

Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 3-Month (PP3M)
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 1-Month (PP1M)
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1307
Study: 28167193

Group type: EXPERIMENTAL
Intervention: Scapula Backward Tipping Test (SBTT)
Number of subjects: 30
Study: 26743288

Group type: EXPERIMENTAL
Intervention: Different oral hygiene maintenance programs
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fixed orthodontic treatment with proper oral hygiene
Number of subjects: 36
Study: 23322707

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) imaging
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional clinical assessment using the OM assessment scale (OMAS)
Number of subjects: 48
Study: 21689069

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of zoledronic acid
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sodium chloride (control)
Number of subjects: 46
Study: 19332467

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 16835383

Group type: EXPERIMENTAL
Intervention: CHVP plus interferon alpha (12 cycles for 18 months)
Number of subjects: 401

Group type: COMPARATOR
Intervention: CHOP followed by high-dose therapy with ASCT (4 cycles)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: CHVP plus interferon alpha
Number of subjects: 401

Group type: COMPARATOR
Intervention: CHOP followed by high-dose therapy with ASCT
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Patients with complete response at end of induction therapy
Number of subjects: 401
Study: 12697371

Group type: EXPERIMENTAL
Intervention: 1200 mg/day elemental calcium and 800 IU/day vitamin D(3) supplementation
Number of subjects: 3270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3270
Study: 11007833

Group type: EXPERIMENTAL
Intervention: High-UFH regimen (HHR) at 90 IU/kg body-weight (b.w.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-UFH regimen (LHR) at 50 IU/kg b.w.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) at 85 IU/kg b.w. (HHR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) at 45 IU/kg b.w. (LHR)
Number of subjects: 10
Study: 9068336

Group type: EXPERIMENTAL
Intervention: Propofol induction followed by a standard propofol infusion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Isoflurane maintenance after propofol induction
Number of subjects: 48
Study: 8437256

Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Norfloxacin (800 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Initial treatment (2-tablet quinolone treatment)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Initial treatment in premenopausal group
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Initial treatment in postmenopausal group
Number of subjects: 125
Study: 3093022

Group type: EXPERIMENTAL
Intervention: 10 micrograms 24R,25(OH)2D3 daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 24R,25(OH)2D3 treatment
Number of subjects: 58
Study: 30427894

Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Exercise (HIFE) Program
Number of subjects: 186

Group type: COMPARATOR
Intervention: Seated social group activity
Number of subjects: 186
Study: 26862746

Group type: EXPERIMENTAL
Intervention: Low-abrasivity gel-to-foam fluoride toothpaste (1,450 ppm NaF)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Medium-abrasivity gel-to-foam fluoride toothpaste (1,450 ppm NaF)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Reference toothpaste (1,450 ppm NaF)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo toothpaste (0 ppm fluoride)
Number of subjects: 56
Study: 24815910

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, and 70 mg/day
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 265
Study: 22650126

Group type: EXPERIMENTAL
Intervention: Low-energy laser irradiation on acupoint and external auditory canal combined with auricular point sticking (APS)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at the same acupoints as those in observation group 1
Number of subjects: 258

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Low-energy laser irradiation and APS
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 258
Study: 20435265

Group type: EXPERIMENTAL
Intervention: Supine position BMD measurement (adjusted for sitting equivalent)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sitting position BMD measurement
Number of subjects: 82
Study: 18661187

Group type: EXPERIMENTAL
Intervention: MT1-MMP-positive expression in peripheral blood
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: MT1-MMP-positive expression in bone marrow
Number of subjects: 810
Study: 15878099

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) - 60.8 Gy in 32 fractions over 26 days, two fractions per day (1.8 Gy and 2.0 Gy) with a 6h gap, 1 week treatment gap after first 12 fractions.
Number of subjects: 229

Group type: COMPARATOR
Intervention: Conventional fractionation (CF) - 64 Gy in 32 fractions over 45 days, one fraction per day, 5 days per week.
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 229
Study: 11955466

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) - 10-20 treatments, 10 Hz, 110% motor threshold applied to the left dorsolateral prefrontal cortex for a total of 10,000-20,000 stimulations
Number of subjects: 25

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT) - 4-12 treatments
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 25
Study: 9564057

Group type: EXPERIMENTAL
Intervention: GnRH analog
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 17
Study: 7634871

Group type: EXPERIMENTAL
Intervention: Theophylline 3 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Theophylline 6 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Theophylline 0 mg/kg (Control)
Number of subjects: 24
Study: 2203382

Group type: EXPERIMENTAL
Intervention: Gerovital
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Another procaine preparation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 911591

Group type: EXPERIMENTAL
Intervention: 2% plain lignocaine 20 ml
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2% lignocaine 20 ml with adrenaline 1:200,000
Number of subjects: 15
Study: 29371382

Group type: EXPERIMENTAL
Intervention: Highly intensive inspiratory muscle training (IMT)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Sham inspiratory muscle training (IMT)
Number of subjects: 611
Study: 25724021

Group type: EXPERIMENTAL
Intervention: Acupuncture at LI4
Number of subjects: 49

Group type: COMPARATOR
Intervention: Local anesthetic injection without acupuncture
Number of subjects: 49
Study: 24012131

Group type: EXPERIMENTAL
Intervention: Intensified intervention (N = 371)
Number of subjects: 738

Group type: COMPARATOR
Intervention: Usual care (N = 367)
Number of subjects: 738
Study: 22299093

Group type: EXPERIMENTAL
Intervention: Three different types of implants from three different manufacturers
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Implants loaded after 8 weeks
Number of subjects: 3
Study: 20555044

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 microg every 6 h for a maximum of four doses
Number of subjects: 185

Group type: COMPARATOR
Intervention: Vaginal misoprostol 400 microg every 12 h for a maximum of four doses
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Both regimens of vaginal misoprostol
Number of subjects: 185
Study: 19040018

Group type: EXPERIMENTAL
Intervention: 1.0 mg/m2 bortezomib combined with dexamethasone
Number of subjects: 23

Group type: COMPARATOR
Intervention: 1.3 mg/m2 bortezomib combined with dexamethasone
Number of subjects: 23
Study: 16021483

Group type: EXPERIMENTAL
Intervention: Donepezil for 30 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 30
Study: 12154491

Group type: EXPERIMENTAL
Intervention: Topical treatment for athlete's foot
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic treatment for athlete's foot
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10235351

Group type: EXPERIMENTAL
Intervention: Prophylactic tropisetron 5 mg orally before anesthesia
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study: 8916060

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily for 2 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily for 2 weeks
Number of subjects: 53
Study: 1763595

Group type: EXPERIMENTAL
Intervention: TIVA using midazolam and alfentanil with flumazenil reversal (n = 15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Balanced anaesthesia using midazolam, alfentanil, and nitrous oxide without flumazenil reversal (n = 13)
Number of subjects: 28
Study: 6356969

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intramuscular fentanyl
Number of subjects: 36
Study: 27480401

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (OMP) 400 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 24706544

Group type: EXPERIMENTAL
Intervention: Ultrasound simulator
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cadaveric specimens and plastic models
Number of subjects: 50
Study: 24984771

Group type: EXPERIMENTAL
Intervention: Virtual simulation training using the ImmersiveTouch simulator
Number of subjects: 20

Group type: COMPARATOR
Intervention: No training (Control Group B)
Number of subjects: 20
Study: 22932279

Group type: EXPERIMENTAL
Intervention: Folate intake from FA-containing prenatal supplement (750 μg/d) plus natural food folate (400 μg/d)
Number of subjects: 75
Study: 20437244

Group type: EXPERIMENTAL
Intervention: Preservative-free (PF) dorzolamide/timolol
Number of subjects: 261

Group type: COMPARATOR
Intervention: Preservative-containing (PC) dorzolamide/timolol
Number of subjects: 261
Study: 17921832

Group type: EXPERIMENTAL
Intervention: Nifedipine CR
Number of subjects: 41

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 41
Study: 16288184

Group type: EXPERIMENTAL
Intervention: Pancuronium 100 microg/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rocuronium 600 microg/kg
Number of subjects: 22
Study: 12060478

Group type: EXPERIMENTAL
Intervention: Product containing active ingredients to restore barrier function and modulate inflammatory response, applied twice a day for one month prior to UVA irradiation.
Number of subjects: 20

Group type: COMPARATOR
Intervention: UVA irradiation (6 J.cm‐2)
Number of subjects: 20
Study: 9973021

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Accelerated tissue-type plasminogen activator (t-PA)
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1138
Study: 7484037

Group type: EXPERIMENTAL
Intervention: Acceleromyography monitoring
Number of subjects: 40

Group type: COMPARATOR
Intervention: No nerve stimulator
Number of subjects: 40
Study: 2187822

Group type: EXPERIMENTAL
Intervention: d‐fenfluramine (15 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6138044

Group type: EXPERIMENTAL
Intervention: midazolam (15 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 31294589

Group type: EXPERIMENTAL
Intervention: Intensive group behavioral treatment (IGBT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Waitlist with psychoeducational resources (WLP)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: IGBT
Number of subjects: 29
Study: 28637047

Group type: EXPERIMENTAL
Intervention: Endobronchial valve treatment (EBV)
Number of subjects: 64